Principles of anti-VEGF dosing in the treatment of neovascular age-related macular degeneration
Age-related macular degeneration (AMD) is a chronic progressive disease regarded as a leading cause of vision impairment in elderly people in industrial countries. Neovascular AMD is characterized by an increased risk of severe vision loss. Intravitreal injections of anti-VEGF medication has become...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Real Time Ltd
2019-08-01
|
| Series: | Российский офтальмологический журнал |
| Subjects: | |
| Online Access: | https://roj.igb.ru/jour/article/view/307 |
| _version_ | 1826569943260332032 |
|---|---|
| author | I. E. Ioshin T. Anoprieva |
| author_facet | I. E. Ioshin T. Anoprieva |
| author_sort | I. E. Ioshin |
| collection | DOAJ |
| description | Age-related macular degeneration (AMD) is a chronic progressive disease regarded as a leading cause of vision impairment in elderly people in industrial countries. Neovascular AMD is characterized by an increased risk of severe vision loss. Intravitreal injections of anti-VEGF medication has become a standard of treatment of neovascular AMD. Clinical trials demonstrate that the use of anti-VEGF helps stabilize the vision in at least 90 % of patients, while 30 to 40 % gain three or more lines of vision (15 ETDRS letters). However, observational studies suggest that there are barriers diminishing the efficacy of anti-VEGF treatment in routine clinical practice. Finding an optimal dosing regimen for anti-VEGF therapy that could maintain treatment efficacy with a lower number of injections and fewer monitoring visits could be a solution. The review discusses the evidence base regarding anti-VEGF dosing principles and analyzes current dosing regimens with regard to their benefits and limitations. |
| first_indexed | 2024-04-10T02:31:36Z |
| format | Article |
| id | doaj.art-9136fbfbd4574a3ab8d0364bb17001a7 |
| institution | Directory Open Access Journal |
| issn | 2072-0076 2587-5760 |
| language | Russian |
| last_indexed | 2025-03-14T11:47:21Z |
| publishDate | 2019-08-01 |
| publisher | Real Time Ltd |
| record_format | Article |
| series | Российский офтальмологический журнал |
| spelling | doaj.art-9136fbfbd4574a3ab8d0364bb17001a72025-03-02T09:51:26ZrusReal Time LtdРоссийский офтальмологический журнал2072-00762587-57602019-08-0112310211210.21516/2072-0076-2019-12-3-102-112241Principles of anti-VEGF dosing in the treatment of neovascular age-related macular degenerationI. E. Ioshin0T. Anoprieva1Clinical Hospital, Office of the President of RussiaBAYER, JSCAge-related macular degeneration (AMD) is a chronic progressive disease regarded as a leading cause of vision impairment in elderly people in industrial countries. Neovascular AMD is characterized by an increased risk of severe vision loss. Intravitreal injections of anti-VEGF medication has become a standard of treatment of neovascular AMD. Clinical trials demonstrate that the use of anti-VEGF helps stabilize the vision in at least 90 % of patients, while 30 to 40 % gain three or more lines of vision (15 ETDRS letters). However, observational studies suggest that there are barriers diminishing the efficacy of anti-VEGF treatment in routine clinical practice. Finding an optimal dosing regimen for anti-VEGF therapy that could maintain treatment efficacy with a lower number of injections and fewer monitoring visits could be a solution. The review discusses the evidence base regarding anti-VEGF dosing principles and analyzes current dosing regimens with regard to their benefits and limitations.https://roj.igb.ru/jour/article/view/307age-related macular degenerationantiangiogenic therapyanti-vegfafliberceptranibizumabdosing regimenspro re natatreat and extend |
| spellingShingle | I. E. Ioshin T. Anoprieva Principles of anti-VEGF dosing in the treatment of neovascular age-related macular degeneration Российский офтальмологический журнал age-related macular degeneration antiangiogenic therapy anti-vegf aflibercept ranibizumab dosing regimens pro re nata treat and extend |
| title | Principles of anti-VEGF dosing in the treatment of neovascular age-related macular degeneration |
| title_full | Principles of anti-VEGF dosing in the treatment of neovascular age-related macular degeneration |
| title_fullStr | Principles of anti-VEGF dosing in the treatment of neovascular age-related macular degeneration |
| title_full_unstemmed | Principles of anti-VEGF dosing in the treatment of neovascular age-related macular degeneration |
| title_short | Principles of anti-VEGF dosing in the treatment of neovascular age-related macular degeneration |
| title_sort | principles of anti vegf dosing in the treatment of neovascular age related macular degeneration |
| topic | age-related macular degeneration antiangiogenic therapy anti-vegf aflibercept ranibizumab dosing regimens pro re nata treat and extend |
| url | https://roj.igb.ru/jour/article/view/307 |
| work_keys_str_mv | AT ieioshin principlesofantivegfdosinginthetreatmentofneovascularagerelatedmaculardegeneration AT tanoprieva principlesofantivegfdosinginthetreatmentofneovascularagerelatedmaculardegeneration |